Ignite Creation Date:
2024-05-05 @ 6:31 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00490906
Status:
COMPLETED
Last Update Posted:
2014-01-22
First Post:
2007-06-21
Brief Title:
Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis
Sponsor:
Nancy Hammond MD
Organization:
University of Kansas Medical Center
Study Overview
Official Title:
Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis A Pilot Study
Status:
COMPLETED
Status Verified Date:
2014-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if certain drugs commonly used to treat multiple sclerosis have an effect on bone health
Detailed Description:
There will be 60 female patients with MS at University of Kansas Medical Center KUMC They will be split into two groups a Copaxone group and an Interferon Avonex Rebif or Betaseron group Each group will be composed of 30 women matched for menopausal status Each subject will be given a questionnaire assessing risk factors for low bone density All patients will have a determination of an Expanded Disability Status Scale EDSS height and weight medical history and fracture history All patients will undergo hip and spine dual x-ray absorptiometry DEXA and will have labs drawn to determine serum 25 hydroxyvitamin D parathyroid hormone ionized calcium estradiol bone-specific acetyl phosphatase osteocalcin and C-peptides
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None